ATTR-CM
FDA Places Clinical Hold on Two Intellia CRISPR Trials After Life-Threatening Liver Toxicity Case
FDA; Intellia; CRISPR; clinical hold; liver toxicity; nexiguran ziclumeran; MAGNITUDE trial; transthyretin amyloidosis; ATTR-CM; ATTR-PN; gene therapy
Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street
Alnylam Pharmaceuticals; market cap; Amvuttra; heart disease; ATTR-CM; stock surge; Q2 2025 earnings; revenue growth
Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny
Intellia Therapeutics; gene therapy; safety event; adverse event; MAGNITUDE trial; liver transaminase; stock decline; ATTR-CM; gene editing; analyst response
Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio
Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy
BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment
Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy
FDA Approves BridgeBio’s Attruby for ATTR-CM, Offering New Hope for Patients
Attruby, BridgeBio, ATTR-CM, FDA approval, transthyretin amyloid cardiomyopathy, acoramidis, TTR stabilizer
FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis
Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment
ICER Report Suggests Significant Price Reduction for Pfizer’s ATTR-CM Drug Tafamidis
Tafamidis, ATTR-CM, ICER, Pricing, Cost-Effectiveness
Vutrisiran Shows Promising Results in Phase 3 Study for ATTR-CM Treatment
Vutrisiran, ATTR-CM, Phase 3 Study, Alnylam Pharmaceuticals, HELIOS-B
Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition
Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis